Four specific GLP-1 medications were examined: semaglutide (Wegovy, Ozempic, Rybelsus), liraglutide (Saxenda), exenatide (Byetta, Bydureon BCise), and dulaglutide (Trulicity)
This article discusses investigational clinical research and regulatory status
Consequent to these results, dulaglutide obtained FDA permission for administration in individuals with an eGFR as low as 15 mL/min per 1.73 m2 (Tuttle et al
La forma inyectable puede ocasionar reacciones en el sitio de inyeccin (enrojecimiento, picazn, hinchazn leve) en aproximadamente 1-3% de pacientes, aunque estas reacciones suelen ser transitorias y leves
A 2025 real-world safety comparison found the two drugs had distinct safety profiles, rather than one being safer overall
Ozempic is generally considered to be a safe choice when taken as prescribed by a healthcare professional